News | October 15, 2021
Shilpa Medicare raises over Rs. 297 crore through preferential allotment
Equity raise to finance growth and investments in the biological space
Equity raise to finance growth and investments in the biological space
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
It strengthens its presence to over 250 stores
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
Shilpa's Paracetamol oral thin films are patent protected and are first of this kind in the world
The company has posted net profit of Rs.147.78 crores for the 12 months period ended March 31, 2021
The GMP certificate is valid for three years until April 2024.
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The commercial production in the SML was started in November 1989.
Subscribe To Our Newsletter & Stay Updated
